ArticleBMJ open2026
Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine oral anticoagulant (OAC) prescription patterns and clinical outcomes, among elderly patients with atrial fibrillation (AF) during the era of widespread direct oral anticoagulant (DOAC) use.
designA retrospective cohort study.
settingThis study used nationwide electronic health records from multiple centres across Israel.
participantsPatients with incident AF aged ≥75 years who were diagnosed between 1 January 2010 and 1 January 2020. OUTCOME MEASURES: Incidence of stroke, intracranial haemorrhage (ICH) and gastrointestinal bleeding (GIB) were estimated as the number of events per 100 person-years. Inverse probability weighting was used to estimate adjusted risk ratios for stroke, ICH, GIB and all-cause mortality.
results45 820 patients were included. The median age was 83 (IQR, 79-83), including 26 590 females (58%); 15 019 received DOAC, 7114 used warfarin and 23 687 were OAC non-users. Overall initial OAC prescription rates increased from 31% in 2010 (100% warfarin) to 66% (98% DOAC) in 2019. Compared with OAC non-users, DOAC-treated patients had decreased risk of stroke (adjusted risk ratio (aRR) 0.71, 95% CI 0.64 to 0.79) and GIB (aRR 0.81, CI 0.74 to 0.90), but similar ICH risk (aRR 0.98, CI 0.84 to 1.16). Warfarin-treated patients had similar risk of stroke (aRR 1.1, CI 0.99 to 1.24), increased risk of ICH (aRR 1.32, CI 1.10 to 1.57) and GIB (aRR 1.13, CI 1.02 to 1.26). Both DOAC (aRR 0.83, CI 0.81 to 0.85) and warfarin (aRR 0.93, CI 0.90 to 0.95) groups had lower mortality risk than OAC non-users.
conclusionsAmong elderly patients with AF, DOAC use increased over time and was associated with favourable clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.